Related Experiment Video
Updated: Oct 12, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
DLX6-AS1: a putative lncRNA candidate in multiple human cancers
Mohsen Sheykhhasan1, Yaghoub Ahmadyousefi1, Reihaneh Seyedebrahimi2
1Department of Molecular Medicine and Genetics, Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Long non-coding RNAs (lncRNAs) regulate gene expression and serve as cancer biomarkers. DLX6-AS1, a lncRNA, functions as an oncogene, impacting cancer development and signaling pathways, offering potential diagnostic and therapeutic targets.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Long non-coding RNAs (lncRNAs) are crucial regulators of gene expression and emerging biomarkers in cancer development.
- Aberrant lncRNA expression is implicated in tumorigenesis and cancer progression.
- DLX6-AS1 is identified as a significant oncogenic lncRNA involved in various cancers.
Purpose of the Study:
- To review and analyze recent research on the biological functions of DLX6-AS1.
- To investigate the impact of DLX6-AS1 on signaling pathways and gene expression in human cancers.
- To explore the potential of DLX6-AS1 and associated pathways as cancer biomarkers and therapeutic targets.
Main Methods:
- Literature review and analysis of existing research studies.
- Examination of molecular mechanisms underlying DLX6-AS1's role in gene expression.
- Assessment of DLX6-AS1's involvement in various cancer signaling pathways.
Main Results:
- DLX6-AS1 acts as an oncogene, influencing cancer development and prognosis.
- DLX6-AS1 affects multiple signaling pathways critical to cancer progression.
- The molecular mechanisms of DLX6-AS1's gene expression regulation are elucidated.
Conclusions:
- DLX6-AS1 plays a significant role in the development and progression of multiple human cancers.
- Signaling pathways modulated by DLX6-AS1 hold promise as diagnostic biomarkers.
- Targeting DLX6-AS1 and its associated pathways presents a potential therapeutic strategy for cancer treatment.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Non-LTR Retrotransposons
Inheritance of Chromatin Structures

